Different effects of growth hormone releasing peptide (GHRP-6) and GH-releasing hormone on GH release in endogenous and exogenous hypercortisolism

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRP-6 in this randomized controlled trial publication.

GHRP-6 is a synthetic hexapeptide that releases GH in several species, including man.

As GHRH and GHRP-6 apparently stimulate GH release by different mechanisms, the researchers evaluated the GH responses to these peptides in patients with endogenous and exogenous glucocorticoid excess and also in control subjects.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a randomized study.

The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

GH was measured by immunofluorometric assay.

IGF-I was determined by radioimmunoassay.

Plasma glucose was measured by the glucose-oxidase technique.

What Was Measured

The subject headings attached to it are Cushing Syndrome, Fluoroimmunoassay, Growth Hormone, Growth Hormone-Releasing Hormone, Hydrocortisone, Oligopeptides and Radioimmunoassay.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and GHRP-6.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1997 (Clinical endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the GHRP-6 compound page, all human trials.